Efficacy and safety of rivaroxaban, colchicine, and famotidine–loratadine with specialist supportive clinical care for fatigue in patients with post-COVID-19 condition in the UK: a multisite, open-label, randomised controlled trial

Study limitation reported by the research below: “The trial is open-label, which is a known risk of bias for subjective patient-reported outcomes like fatigue scales.”